Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: Prognostic implications and clinical significance for invasion and metastasis

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 6998-7003

  Miyata, Yasuyoshi ^a   Iwata, Takahisa ^a   Ohba, Kojiro ^a   Kanda, Shigeru ^b   Nishikido, Masaharu ^a   Kanetake, Hiroshi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; MATRILYSIN;

ADULT; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33845796579     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1626     Document Type: Article

References (49)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
2. Ellis LM, Filder IJ. Angiogenesis and metastasis. Eur J Cancer 1996;32A:895-904.
3. Stetler-Stevenson W, Liotta LA, Kleiner DE. Extracellular matrix 6: role of matrix metalloproteinases in human tumor invasion and metastasis. FASEB J 1993;15:1434-41.
4. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteinases and their inhibitors in tumor invasion, metastasis, and angiogenesis. Eur Respir J 1994;7:2062-72.
5. Egelblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
6. Mignatti P, Tsuboi R, Robbins E, Rifkin DE. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989;108:671-82.
7. Nagashima Y, Hasegawa S, Koshikawa N, et al. Expression of matrilysin in vascular endothelial cells adjacent to matrilysin-producing tumors. Int J Cancer 1997;72:441-5.
8. Huo N, Ichikawa Y, Kamiyama M, et al. MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Lett 2002;177:95-100.
9. Davidson B, Goldberg I, Gotlieb WH, et al. High levels of MMP-2, MMP-9, MT1-MMP, and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17:799-808.
10. Herbst RS, Yano S, Kuniyasu H, et al. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 2000;6:790-7.
11. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000;6:4823-30.
12. Uzzo RG, Cherullo EE, Myles J, Novick AC. Renal cell carcinoma invading the urinary collecting system: implication for staging. J Urol 2002;167:2392-6.
13. Lein M, Jung K, Laube C, et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 2000;85:801-4.
14. Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001;158:735-43.
15. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 2003;9:1741-9.
16. Hagemann T, Gunawan B, Schulz M, Füzesi L, Binder C. mRNA expression of matrix matalloproteases and their inhibitors differs in subtypes of renal cell carcinomas. Eur J Cancer 2001;37:1839-46.
17. Dekel Y, Koren R, Kugel V, Livne PM, Gal R. Significance of angiogenesis and microvascular invasion in renal cell carcinoma. Pathol Oncol Res 2002;8:129-32.
18. McDonnell S, Navre M, Coffey RJ, Matrisian LM. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 1991;4:527-33.
19. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT. Expression of metalloproteinases genes in human prostate cancer. J Cancer Res Clin Oncol 1991;117:144-50.
20. Bramhall SR, Neoptolemos JP, Stamp GWH, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997;182:347-55.
21. Bolon I, Devouassoux M, Robert C, Moro D, Brambilla C, Brambilla E. Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am J Pathol 1997;150:1619-29.
22. Yamamoto H, Adachi Y, Itoh F, et al. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 1999;59:3313-6.
23. Masaki T, Matsuoka H, Sugiyama M, et al. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 2001;84:1317-21.
24. Crawford HC, Scoggins CR, Washington MK, Matrisian LM, Leach SD. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest 2002;109:1437-44.
25. Zeng ZS, Shu WP, Cohen AM, Guillem JG. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 2002;8:144-8.
26. Leeman MF, Curran S, Murray GI. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 2003;201:528-34.
27. Jones LE, Humphreys MJ, Campbell F, Neoptolemons JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004;10:2832-45.
28. Jiang WG, Davies G, Martin TA, et al. Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 2005;11:6012-9.
29. Fuhrman SA, Lasky LC, Limas CL. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Pathol 1982;6:655-63.
30. Li Y-J, Wei Z-M, Meng Y-X, Ji X-R. β-Catenin up-regulates the expression of cyclin D1, c-myc, and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol 2005;11:2117-23.
31. Leinonen T, Pirinen R, Böhm J, Johansson R, Ropponen K, Kosma V-M. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, β-catenin, and prognosis. Lung Cancer 2006;51:313-21.
32. Sumi T, Nakatani T, Yoshida H, et al. Expression of matrix metalloproteinase 7 and 2 in human renal cell carcinoma. Oncol Rep 2003;10:567-70.
33. Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM. Expression of gelatinase A and B, stromelysin-3, and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998;16:577-85.
34. Kumaki F, Matsui K, Kawai T, et al. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol 2001;159:2125-35.
35. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997;94:1402-7.
36. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
37. Impola U, Uitto VJ, Hietanen J, et al. Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol 2004;202:14-22.
38. Gu ZD, Li JY, Li M, et al. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol 2005;100:1835-43.
39. Adachi Y, Yamamoto H, Itoh F, et al. Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. Int J Cancer 2001;95:290-4.
40. Streubel B, Chott A, Huber D, et al. Lymphomaspecific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004;351:250-9.
41. Macaulay VM, O'Byrne KJ, Saunders MP, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999;5:513-20.
42. Jones L, Ghaneh P, Humphreys M, Neoptolemos JP. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann N Y Acad Sci 1999;880:288-307.
43. Gatto C, Rieppi M, Borsotti P, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 1999;5:3603-7.
44. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36:1621-30.
45. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of the phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203.
46. Arlt MC, Kopitz C, Pennington KL, et al. Increase in gelatinase- specificity of matrix metalloproteinase inhibitors correlated with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res 2002;62:5543-50.
47. Hasegawa S, Koshikawa N, Momiyama N, et al. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 1998;76:812-6.
48. Miyazaki K, Koshikawa N, Hasegawa S, et al. Matrilysin as a target for chemotherapy for colon cancer: use of antisense oligonucleotides as antimetastatic agents. Cancer Chemother Pharmacol 1999;43:S52-5.
49. Wielockx B, Libert C, Wison C. Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation? Cytokine Growth Factor Rev 2004;15:111-5.